GSK Hones OTCs As “Sharp End” Of Consumer Products Business
This article was originally published in The Tan Sheet
Executive Summary
Glaxo’s OTC business is “the very best end of consumer goods as opposed to being a poor relation of pharmaceuticals,” says Emma Walmsley, GSK Consumer Healthcare president.
You may also be interested in...
Glaxo Launches Flonase OTC, Banks On More Consumer Growth Drivers
CEO Andrew Witty says the consumer business GSK is forming through brand divestitures and its JV with Novartis is a part of “the company I've been trying to create for seven years.” GSK’s OTC Flonase reached U.S. stores Feb. 3, a sign of additional product launches he expects the consumer health JV to do.
Glaxo Launches Flonase OTC, Banks On More Consumer Growth Drivers
CEO Andrew Witty says the consumer business GSK is forming through brand divestitures and its JV with Novartis is a part of “the company I've been trying to create for seven years.” GSK’s OTC Flonase reached U.S. stores Feb. 3, a sign of additional product launches he expects the consumer health JV to do.
Emerging Markets Drive Consumer Health Growth, Pose Challenges
Developing markets account for 50% of the global self-care product sales, but close to 100% of the sector’s growth, according to market research firm IMS Health. This picture will continue as OTC drugs and dietary supplements have a bigger health care role in developing countries than in developed markets.